Darcy K. Berry, MS, LCGC

Ms. Darcy K. Berry, MS, LCGC

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in JCO Precision Oncology
Verified
Journal Article
Closed access
DLDarcy K. Berry, MS, LCGC
Darcy K. Berry, MS, LCGC
Xia WangXia Wang
Xia Wang
SMScott T. Michalski
Scott T. Michalski
HKHio Chung Kang
Hio Chung Kang
SYShan Yang
Shan Yang
JHJ. Kevin Hicks
J. Kevin Hicks

11 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RMRuoyu Miao
Ruoyu Miao
KBKirsten Blue
Kirsten Blue
KSKatelyn Sommerer
Katelyn Sommerer
ASAnand Shah
Anand Shah
SBSalvatore Bottiglieri
Salvatore Bottiglieri
DKDae Won Kim
Dae Won Kim
Background: Limited data are available regarding the anticancer activity of PARP inhibitors (PARPis) in pancreatic cancer with mutations in HRR genes other than BRCA and PALB2. Methods: We retrospectively reviewed the clinical characteristics and outcomes of 48 patients with advanced pancreatic cancer harboring pathogenic germline and/or somatic HRR mutations who were treated with PARPis. Results: Thirty patients had germline (g)HRR mutations only, twelve had somatic (s)HRR mutations only, and six had concomitant gHRR and sHRR mutations. The objective response rate (ORR) was 22%. The median progression-free survival (mPFS) and overall survival (mOS) were 6.9 and 11.5 months, respectively. Five patients received olaparib in the front-line setting due to borderline performance status. Their ORR was 20%, and their mPFS and mOS were both 11.3 months. The ORR was higher in patients with BRCA or PALB2 mutations (germline or somatic) than in those with non-BRCA/PALB2 mutations. Patients with somatic non-BRCA/PALB2 variants had a shorter mPFS. Patients with concomitant gHRR/sHRR mutations or gHRR mutations alone had a significantly longer mPFS than those with sHRR mutations only. Conclusions: PARP inhibitors may be considered for patients with advanced pancreatic cancer harboring pathogenic alterations of BRCA who cannot tolerate standard chemotherapy. Maintenance PARPis can be considered in selected patients with non-BRCA/non-PALB2 HRR mutations.

16 September 2023 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
DLDarcy K. Berry, MS, LCGC
Darcy K. Berry, MS, LCGC
NGNancy Gillis
Nancy Gillis
EPEric Padron
Eric Padron
CMColin Moore
Colin Moore
LBLaura V. Barton
Laura V. Barton
TKTodd C. Knepper
Todd C. Knepper

17 October 2022 in Clinical Genetics
Verified
Journal Article
Closed access
CWChelsey B. Weatherill
Chelsey B. Weatherill
SBSarah A. Burke
Sarah A. Burke
CHCarolyn G. Haskins
Carolyn G. Haskins
DLDarcy K. Berry, MS, LCGC
Darcy K. Berry, MS, LCGC
JHJeanne P. Homer
Jeanne P. Homer
Sourat DarabiSourat Darabi
Sourat Darabi